Literature DB >> 18020532

Drug treatment of chronic heart failure in the elderly.

Gregor Leibundgut1, Matthias Pfisterer, Hans-Peter Brunner-La Rocca.   

Abstract

Congestive heart failure is a growing public health problem worldwide, particularly in the elderly population, in whom it has a substantial impact on quality of life and survival. Despite the fact that heart failure is the most common reason for hospitalisation over the age of 65 years, most clinical trials have excluded the elderly population. This is unfortunate because it may not be generally assumed that elderly patients are similar to younger ones. Nonspecific symptoms and co-morbidities in the elderly may make diagnosis of heart failure difficult. In addition, physiology changes with age, polypharmacy complicates therapy and the aim of therapy may change in the presence of co-morbidities such as cancer or dementia. Furthermore, drug interactions and adverse effects are frequent in heart failure in general, but increase significantly with age. Nevertheless, there is little evidence that treatment of heart failure should be fundamentally different in elderly patients compared with younger patients, although careful monitoring of medical therapy is of particular importance in elderly heart failure patients. Therefore, general guidelines on diagnosis and therapy of heart failure also apply to elderly patients, but therapy may need to be adjusted to cater for individual needs, potential interactions and altered elimination of drugs. This article summarises the evidence available for treatment in elderly patients with heart failure, discusses potential differences in elderly subjects compared with their younger counterparts and provides recommendations for clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18020532     DOI: 10.2165/00002512-200724120-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  101 in total

1.  COMET: a proposed mechanism of action to explain the results and concerns about dose.

Authors:  Ake Hjalmarson; Finn Waagstein
Journal:  Lancet       Date:  2003-09-27       Impact factor: 79.321

Review 2.  Cardiovascular physiology-changes with aging.

Authors:  Melvin D Cheitlin
Journal:  Am J Geriatr Cardiol       Date:  2003 Jan-Feb

Review 3.  Keeping your patient with heart failure safe: a review of potentially dangerous medications.

Authors:  Celene M Amabile; Anne P Spencer
Journal:  Arch Intern Med       Date:  2004-04-12

Review 4.  Secondary prevention of coronary heart disease in the elderly.

Authors:  Christopher J Bulpitt
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

5.  Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995.

Authors:  K MacIntyre; S Capewell; S Stewart; J W Chalmers; J Boyd; A Finlayson; A Redpath; J P Pell; J J McMurray
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

6.  Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry).

Authors:  Giovanni Pulignano; Donatella Del Sindaco; Luigi Tavazzi; Donata Lucci; Marco Gorini; Francesco Leggio; Maurizio Porcu; Marino Scherillo; Cristina Opasich; Andrea Di Lenarda; Michele Senni; Aldo Pietro Maggioni
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

7.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

8.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

9.  One-year mortality among unselected outpatients with heart failure.

Authors:  J Muntwyler; G Abetel; C Gruner; F Follath
Journal:  Eur Heart J       Date:  2002-12       Impact factor: 29.983

10.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.

Authors:  Aldo P Maggioni; Inder Anand; Sidney O Gottlieb; Roberto Latini; Gianni Tognoni; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

View more
  4 in total

1.  [Heart failure patients in Primary Care: aging, comorbidities and polypharmacy].

Authors:  Gisela Galindo Ortego; Inés Cruz Esteve; Jordi Real Gatius; Leonardo Galván Santiago; Carmen Monsó Lacruz; Plácido Santafé Soler
Journal:  Aten Primaria       Date:  2010-12-22       Impact factor: 1.137

2.  Managing chronic diseases in the frail elderly: More than just adhering to clinical guidelines.

Authors:  Barbara Farrell; Salima Shamji; Dan Dalton
Journal:  Can Pharm J (Ott)       Date:  2014-03

Review 3.  Heart failure in the elderly: ten peculiar management considerations.

Authors:  Feras Bader; Bassam Atallah; Lisa F Brennan; Rola H Rimawi; Mohammed E Khalil
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

4.  Use of a homecare electronic health record to find associations between patient characteristics and re-hospitalizations in patients with heart failure using telehealth.

Authors:  Kavita Radhakrishnan; Cynthia S Jacelon; Carol Bigelow; Joan Roche; Jenna Marquard; Kathryn H Bowles
Journal:  J Telemed Telecare       Date:  2013-03-25       Impact factor: 6.184

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.